Clinical Trial

A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multi-center, randomized, double-blind, phase III study to evaluate the efficacy and safety of CS1001 in combination with platinum-containing chemotherapy versus placebo in combination with chemotherapy in first-line treatment-naive subjects with stage IV non-small cell lung cancer (NSCLC).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2018-12-27; most recent amendment 2025-07-21.
Status change: Recruiting → Active, Not Recruiting 2021-02-18
Trial Details
NCT Number NCT03789604
Lead Sponsor CStone Pharmaceuticals
Conditions Non Small Cell Lung Cancer
Enrollment 479 participants
Start Date 2018-12-13
Primary Completion 2023-05-15 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-24